Browse the evidence

Obesity has reached epidemic proportions, leading to increased morbidity, disability, health care expenditures, and mortality.

Health practitioners should recognize the widespread impact of obesity on health outcomes.

Nonsurgical options for obesity treatment are limited.

Healthcare providers should be aware of the limited treatment options available for obesity.

Benefits of the intervention were not evident for those entering the trial with a history of cardiovascular disease.

Practitioners should consider individual health histories when recommending lifestyle interventions.

Consumption of both dietary plant and animal protein was not related to the risk of total CHD and HTN.

Neither plant nor animal protein intake is linked to increased risk of CHD or HTN.

The risk of CHD and HTN did not change significantly with increasing dietary total protein intake from 10% to 25% of total calorie intake.

Increasing total protein intake within this range does not affect CHD or HTN risk.

Use of second generation oral contraceptives (OC) did not significantly improve muscle adaptations to 10 weeks of resistance training compared with nonusers.

Practitioners should note that second generation OCs do not enhance resistance training adaptations in untrained young women.

Current hypertension guidelines do not yet recommend incretin-based therapies as first-line treatment because no large-scale trial has used blood pressure reduction as its primary endpoint, despite robust secondary data showing efficacy.

You cannot currently get GLP-1 medications prescribed specifically for high blood pressure as a first-line treatment under standard insurance guidelines. They are primarily approved for diabetes and weight loss. However, if you have both hypertension and obesity/diabetes, your doctor may prescribe them for those conditions, which will incidentally lower your blood pressure significantly.

Antidiabetic medications can reduce the risk and improve outcomes of cardiovascular diseases.

Consider the cardiovascular benefits when prescribing antidiabetic medications.

The extra amount of protein led to minor changes in body composition but not physical performance or muscle quality.

Practitioners should manage expectations regarding the impact of increased protein on physical performance and muscle quality.

Higher carbohydrate intake is associated with a significant increase in total cardiovascular disease (CVD) events (HR=1.05, 95% CI: 1.00, 1.10).

Practitioners should consider the potential risks of high carbohydrate intake on cardiovascular health.

No significant association was found between dietary carbohydrate and CVD mortality (HR=1.02; 95% CI: 0.91, 1.14).

Dietary carbohydrate intake may not significantly impact CVD mortality, suggesting other factors may be more influential.

Glucose metabolic clearance rate was depressed after training (P < 0.05).

Training may lead to a reduced ability to clear glucose from the bloodstream during exercise.

Training did not elicit changes in the maximal activities of citrate synthase and malate dehydrogenase.

Short-term training may not enhance certain mitochondrial enzyme activities.

Obesity prevalence is projected to grow by 40% in the next decade.

Healthcare practitioners should prepare for increased obesity-related health issues.

FIM programs often prioritize health equity.

Health care providers should ensure that FIM interventions are designed to promote health equity.

A higher state of energy flux may enhance the sensitivity between energy intake and expenditure.

Encouraging higher energy expenditure may improve clients' ability to manage their weight effectively.

There were no significant differences in mean values for %fat and fat-free mass between pretesting, post-testing, and delta data.

The lack of significant differences suggests consistency in body composition measurements.

New approaches in GLP-1RAs development include multi-agonists and combination therapies.

Practitioners should explore the potential benefits of multi-agonist and combination therapy strategies in GLP-1RA treatments.

Novel GLP-1-based therapeutics are rapidly advancing and may reshape the future landscape of obesity and type 2 diabetes treatment.

Practitioners should consider the potential of these novel agents in treating obesity and type 2 diabetes.

Triple agonists such as retatrutide target GIP, GLP-1, and glucagon receptors to amplify metabolic effects.

Consider the potential of triple agonists in enhancing metabolic outcomes for patients.

The use of mixed methods does not reach acceptable accuracy for 1RM prediction on an individual basis.

Practitioners should be cautious when using mixed methods for individual 1RM predictions.

There are concerns regarding the long-term safety and efficacy of GLP-1 receptor agonists.

Practitioners should monitor patients closely for safety and efficacy when prescribing GLP-1 receptor agonists.

The study of exercise as a preventative or therapeutic treatment is increasingly interdisciplinary and impactful.

Researchers and practitioners should collaborate across disciplines to enhance exercise interventions.

Meta-regression suggested no significant correlation between BP reduction and baseline characteristics such as age, gender, HbA1c, weight, BMI, and percentage of patients with hypertension.

GLP-1 receptor agonists may be effective for BP management regardless of certain baseline characteristics.